#SAIA @southasianibd Swag ! Getting excited !!!

The current #treatment paradigm in #IBD according to Parakkal Deepak MD, MS, FACG of @southasianIBD: 💊Right intervention 🏥Right #patient 🎯Right target ••• He further noted #physicians needs to begin considering #cultural concerns when choosing a #therapy #DDW23

Parakkal Deepak MD, MS, FACG Is #T2T possible across diverse populations including in South Asian population ? Cultural concerns : an additional consideration Hurdles need working through #DDW2023 @southasianIBD

Thanks for the swag ⁦Tina Aswani-Omprakash, MPH⁩. Proud to support ⁦@southasianIBD⁩. Break the silence. ⁦Digestive Disease Week⁩

For #WorldIBDDay & #MentalHealthAwarenessMonth, IBDesis presents a virtual support group led by maha (she/her) and Sharan! 🙌💬 Join us on Saturday, May 20th at 8.30am / 11.30 am EST / 4.30 pm BST / 8:30pm PKT / 9 pm IST! Sign up here - forms.gle/R4Bn8tJEkWgmoi…

Happy #WorldIBDDay from all of us at #SAIA /IBDesis/IBDJournalClub! Listen to our lead Patient Advocate (UK) Sharan explain SAIA's vision for the #SouthAsianIBD community across the world 💥 Together we will build a more accessible and equitable world for all 🙏🏽🙏🏽

Coming up!! Parsa Trust / Project ECHO Pakistan joins hands with us at #SAIA to bring forward our CME event! 🙌 IBD in Pediatrics Presented by M. Adnan Altaf, MD, FAAP 31st May, 10pm PKT / 1pm EST / 6pm BST Zoom code: 851 6049 8338

SAIA's #IBDClub is thrilled to host its next session! Vikash, MD, PGY-1 @JacobiHosp, Albert Einstein College of Medicine - Official reviews 'Real-World Evidence Comparing VDZ & UST in aTNF-Experienced Patients w/ Crohn's Disease' Access the article here: bit.ly/3W3CHqO Join us on 2nd June at IBDJournalClub!

Dr Adnan Altaf will be presenting today "IBD in pediatrics" to physicians of Pakistan through our joint @southasianIBD and PARSA ECHO Pakistan project.

Join us today. Don't forget to register!

Tune in on June 2nd, 12 :00 PM Central time for the IBDJournalClub @southasianIBD presentation by Vikash, MD on #redjournal AJG - The American Journal of Gastroenterology ACG article comparing Vedolizumab & Ustekinumab in Anti TNF Experienced Patients w/ Crohn's Disease 📽️ youtu.be/5mIr20FnAvc

📢🚨Tune in today, 12 :00 PM CT for the IBDJournalClub @southasianIBD presentation on #redjournal AJG - The American Journal of Gastroenterology ACG article comparing Vedolizumab & Ustekinumab in Anti TNF Experienced Patients w/ Crohn's Disease 📽️ youtu.be/5mIr20FnAvc

Kicking off our Patient Education Series with a vital talk to demystify & destigmatize IBD medications💥💥 Featuring the one & only Prof Vineet Ahuja AIIMS, New Delhi 🇮🇳 & the amazing #SAIA team Neilanjan Nandi, MD, FACG, AGAF, FCCF, FACP Tina Aswani-Omprakash, MPH Madhura Balasubramaniam Join us on June 17th: facebook.com/SouthAsianIBD/

Coming up!! ▶️▶️ Parsa Trust / Project ECHO Pakistan joins hands with us at #SAIA to bring forward our next CME event 🔽 IBD – Drug Therapy Presented by Dr. Waqqas Afif, MD, MSc. (Epi), FRCP(C) Wed, 21st June 2023 at 10pm PKT / 1pm EST / 6pm BST Zoom code: 819 0049 2294

Going live in just a few hours! Join us as we bring more #IBD CME education to PCPs & GIs in #Pakistan 🇵🇰 @southasianIBD Project ECHO Tauseef Ali MD, FACG AGAF FACP Waqqas Afif, MD Sabina Ali,MD Jalpa Devi

SAIA's #IBDClub is thrilled to host its next session! Talal khurshid Bhatti , GI Fellow SZABMU reviews 'Early Intervention with biological therapy in Crohn's disease - how early is early?' Access the article here: doi.org/10.1093/ecco-j… Join us on 7th July at IBDJournalClub!

Here is the 📽️ link to the July 7th presentation by Talal khurshid Bhatti on "Early Intervention with biologic therapy in Crohn's Disease- How early is early? " youtu.be/TSJGTJO_5BA

🌼As a first-year Gastroenterology fellow, you're embarking on an exciting journey in a specialized field of medicine 🌼Here are some advice and tips to help you navigate your first year successfully! 🌼Remember, the first year of fellowship is just the beginning of your journey

🎯 Treat-to-Target (T2T) is revolutionizing #IBD care — aiming beyond symptom control toward deep remission using objective markers like biomarkers, endoscopy, and histology. ✅ Benefits? 💡Higher mucosal healing 💡Fewer complications 💡Personalized, proactive therapy ⚠️ But